169 related articles for article (PubMed ID: 8845575)
1. Modulation of multidrug resistance in multiple myeloma.
Sonneveld P
Baillieres Clin Haematol; 1995 Dec; 8(4):831-44. PubMed ID: 8845575
[TBL] [Abstract][Full Text] [Related]
2. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
3. The role of P-glycoprotein in drug resistance in multiple myeloma.
Abraham J; Salama NN; Azab AK
Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
5. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.
Dalton WS; Crowley JJ; Salmon SS; Grogan TM; Laufman LR; Weiss GR; Bonnet JD
Cancer; 1995 Feb; 75(3):815-20. PubMed ID: 7828131
[TBL] [Abstract][Full Text] [Related]
6. Modulation of multidrug resistance (MDR) in hematological malignancies.
Covelli A
Ann Oncol; 1999; 10 Suppl 6():53-9. PubMed ID: 10676553
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
Sonneveld P; Suciu S; Weijermans P; Beksac M; Neuwirtova R; Solbu G; Lokhorst H; van der Lelie J; Dohner H; Gerhartz H; Segeren CM; Willemze R; Lowenberg B; ; ;
Br J Haematol; 2001 Dec; 115(4):895-902. PubMed ID: 11843823
[TBL] [Abstract][Full Text] [Related]
8. A bioassay for the activity of PSC 833 in human serum for modulation of P-glycoprotein-mediated multidrug resistance.
Uchiyama-Kokubu N; Watanabe T; Nakajima M
Anticancer Drugs; 2000 Aug; 11(7):583-90. PubMed ID: 11036963
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance in multiple myeloma.
Sonneveld P; Lokhorst HM; Vossebeld P
Semin Hematol; 1997 Oct; 34(4 Suppl 5):34-9. PubMed ID: 9408959
[TBL] [Abstract][Full Text] [Related]
12. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
Salmon SE; Dalton WS; Grogan TM; Plezia P; Lehnert M; Roe DJ; Miller TP
Blood; 1991 Jul; 78(1):44-50. PubMed ID: 1676918
[TBL] [Abstract][Full Text] [Related]
13. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study.
Ivy SP; Olshefski RS; Taylor BJ; Patel KM; Reaman GH
Blood; 1996 Jul; 88(1):309-18. PubMed ID: 8704189
[TBL] [Abstract][Full Text] [Related]
14. Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells.
Wyler B; Shao Y; Schneider E; Cianfriglia M; Scheper RJ; Frey BM; Gieseler F; Schmid L; Twentyman PR; Lehnert M
Br J Haematol; 1997 Apr; 97(1):65-75. PubMed ID: 9136943
[TBL] [Abstract][Full Text] [Related]
15. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.
Sonneveld P; Durie BG; Lokhorst HM; Marie JP; Solbu G; Suciu S; Zittoun R; Löwenberg B; Nooter K
Lancet; 1992 Aug; 340(8814):255-9. PubMed ID: 1353189
[TBL] [Abstract][Full Text] [Related]
16. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.
Pu YS; Hsieh TS; Cheng AL; Tseng NF; Su IJ; Hsieh CY; Lai MK; Tsai TC
Br J Urol; 1996 Jan; 77(1):76-85. PubMed ID: 8653321
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
19. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression.
Chao CC
FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484
[TBL] [Abstract][Full Text] [Related]
20. Characterization and modulation of transitional cell carcinoma cell lines with acquired multidrug resistance.
Yu DS; Chang SY; Ma CP
Br J Urol; 1998 Feb; 81(2):234-40. PubMed ID: 9488065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
